Pancreatic Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036

Pancreatic Cancer Market Outlook and Forecast

Thelansis's "Pancreatic Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pancreatic Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pancreatic Cancer Overview

Pancreatic cancer is a heterogeneous group of malignancies arising in the pancreas, with pancreatic ductal adenocarcinoma (PDAC) representing the predominant form. Early-stage disease may produce few or nonspecific symptoms, resulting in frequent diagnosis at locally advanced or metastatic stages. Clinical manifestations can include jaundice, abdominal or back pain, unexplained weight loss, anorexia, digestive disturbances, and new-onset diabetes, although presentation varies with tumor location and disease extent. Treatment is guided by stage, resectability, tumor biology, and patient fitness and may involve surgery, chemotherapy, radiation, targeted therapy, or multimodal combinations. Molecular profiling can identify patients with actionable alterations involving homologous-recombination repair, mismatch repair, gene fusions, HER2, and selected KRAS variants. The treatment landscape is evolving, with KRAS-directed therapy now entering clinical practice for previously treated metastatic PDAC. Despite advances, tumor heterogeneity, stromal barriers, metastatic spread, and acquired resistance continue to limit durable disease control.

Key Highlights

• In the United States, pancreatic cancer incidence cases are projected to increase from 66,470 in 2026 to 73,061 by 2036.
• Pancreatic cancer is an aggressive malignancy often diagnosed at an advanced stage.
• High recurrence rates and limited treatment options remain major clinical challenges.
• Significant unmet need remains for early detection and therapies that improve survival.

Market Overview

• The Germany pancreatic cancer market is projected to grow from $255M in 2026 to $745M by 2036.
• Market growth is driven by:
• Increasing adoption of targeted therapies and novel treatment combinations
• Advances in precision oncology and immunotherapy research

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026-2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Eli Lilly and Company
• Philogen S.p.A.
• Lytix Biopharma AS
• Thermosome GmbH
• ImmunoGenesis
• Intensity Therapeutics, Inc.
• MedSIR
• Beijing Biostar Pharmaceuticals Co., Ltd.
• Iovance Biotherapeutics, Inc.
• SOTIO Biotech a.s.
• Sonnet BioTherapeutics
• Advenchen Pharmaceuticals, LLC.
• Tcelltech Inc.